ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1347

Poor Health-Related Quality of Life in Patients with Lupus Nephritis

Cristina Arriens1, Janice Ma2, Konrad Pisarczyk2, Richard Leff3, Kiruthi Palaniswamy4 and Li Long4, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Maple Health Group, LLC, New York, NY, 3Kezar Life Sciences, South San Francisco, CA, 4Kezar Life Sciences, Inc., South San Francisco, CA

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, Epidemiology, Lupus nephritis, Patient reported outcomes, quality of life

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Patient Outcomes, Preferences, and Attitudes Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematosus (SLE) associated with considerable morbidity that has a devastating impact on a patient’s life. Little is known about true impact of LN on health-related quality of life (HRQoL) in patients with SLE. The objective of our study was to review and summarize evidence on the humanistic burden of LN in adult and juvenile patients.

Methods: A targeted literature review was conducted in MEDLINE/Pubmed and Embase to identify studies in adult and juvenile patients with diagnosed LN. A search strategy was developed separately for the two databases to identify relevant peer-reviewed articles published in English between March 2012 and March 2022, and conference abstracts indexed in Embase since 2019. All records were screened by a single reviewer according to pre-specified inclusion and exclusion criteria.

Results: Of 4,126 records identified in the medical databases, 10 non-interventional studies evaluated HRQoL in adult (n=9) and juvenile (n=1) SLE patients with LN. Six studies included patients from the US. The remaining studies were conducted in multiple countries worldwide including US (n=2), Latin America (n=1) and Switzerland (n=1). Additional interventional studies evaluating treatment effect on patient HRQoL were identified and analyses are ongoing. Adults with active LN reported poor scores in almost all domains of the SF-36 suggesting a deterioration in multiple aspects of life, such as physical and emotional functioning. The patient-perceived burden of active LN was more pronounced than other SLE organ system manifestations. Furthermore, active LN significantly impacted HRQoL measured by lupus-specific questionnaires including LupusPRO and LupusQoL, compared to inactive LN patients or non-LN SLE patients. The greatest impact of LN was demonstrated on procreation, physical, and emotional functioning. Three studies examined the perspectives of LN patients on facilitators of decision-making and satisfaction of disease control and treatment. Dissatisfaction was reported by one third of nephrology physicians and 25% of patients and was associated with LN severity and various signs and symptoms of disease. Patients with LN indicated that restoring health, improved quality of life, and effective patient-physician communication regarding benefits and harms as the most relevant aspects of treatment. Children with LN on glucocorticoid therapy had reduced attention and worse problem internalization as reported by their parents using the Behavior Assessment of Childhood Disorders (BASC-2).

Conclusion: SLE patients with LN suffer from poor HRQoL across multiple domains of life, including physical and emotional health, especially during periods of active renal disease. One in four patients with LN are dissatisfied with their disease control, indicating a high unmet need for effective therapies and room for LN management improvement.


Disclosures: C. Arriens, AstraZeneca, Aurinia, Bristol-Myers Squibb(BMS), GlaxoSmithKlein(GSK); J. Ma, Kezar Life Sciences, Inc.; K. Pisarczyk, Kezar Life Sciences Inc.; R. Leff, Kezar Life Sciences; K. Palaniswamy, Kezar Life Sciences, Inc.; L. Long, Kezar Life Sciences, Inc..

To cite this abstract in AMA style:

Arriens C, Ma J, Pisarczyk K, Leff R, Palaniswamy K, Long L. Poor Health-Related Quality of Life in Patients with Lupus Nephritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/poor-health-related-quality-of-life-in-patients-with-lupus-nephritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/poor-health-related-quality-of-life-in-patients-with-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology